Inside information
11:20 Finnish time / 10:20 Swedish time
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ON
The nanoenzalutamide tablet formulation was developed in a partnership with the ONConcept® Consortium (Bluepharma, Helm, and Welding) whereby Nanoform's proprietary controlled expansion of supercritical solutions (CESS®) technology provides the opportunity for an improved and differentiated finished product. Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a 160mg, single tablet per day regimen may be preferable for patients in need of reducing their total number of daily pills.
The single-dose, randomized, comparative bioavailability study, which was performed by a contract research organization (CRO) in
A patent application for the nanoenzalutamide formulation has already been jointly filed by Helm and Nanoform. We aim for the product launch after the expiry of the enzalutamide substance patent in the respective territories. For
"We are delighted to have achieved promising results from this clinical trial, bringing closer the prospect of making the lives of prostate cancer patients around the world easier in their daily struggle managing this common disease", said Dr. Edward Haeggström, Chief Executive Officer of Nanoform. "This program exemplifies the opportunity available to create novel and improved dosage forms of existing medicines and to ensure that those drugs in clinical development are patient-centric before they reach the market. Together with our ONConcept® Consortium partners, we look forward to executing licensing deals this year and in the future to commercialize nanoenzalutamide."
[1] Xtandi is a registered trademark of
[2] Source: xtandi.com
Nanoform will present the conclusions in a live webcast presentation and conference call on
The presentation will be broadcast live as a webcast available at:
https://ir.financialhearings.com/pressconf-january-2024
Teleconference dial-in numbers:
Register using the link below to receive dial-in details and a conference ID for the webinar and conference call.
https://conference.financialhearings.com/teleconference/?id=5001857
For further information, please contact:
Christian.jones@nanoform.com
+44 7804 474 771
For investor relations queries, please contact:
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
About ONConcept® Consortium
The three independent and certified European pharmaceutical companies - Bluepharma, Helm and Welding - joined forces in 2019 after identifying a significant opportunity for a leading partnership that can develop and manufacture complex, differentiated and highly potent products for licensing to pharmaceutical companies operating in markets around the world. ONConcept® consortium develops a portfolio of more than 15 molecules and makes them available for licensing and distribution by pharmaceutical companies around the world. The consortium is based on a profound international network and global experience in value-added products, in-house scientific-, IP-, regulatory-, and commercial expertise to be in the position to offer services covering the entire value chain according to customer needs.
Bluepharma (
WELDING (
Nanoform Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended
https://news.cision.com/nanoform/r/inside-information-made-public--nanoform-announces-important-milestone-with-promising-clinical-resul,c3916282
https://mb.cision.com/Main/18905/3916282/2564958.pdf
(c) 2024 Cision. All rights reserved., source